Scalper1 News
Big pharma Eli Lilly (LLY) and its biotech partner Incyte (INCY) said Wednesday that their rheumatoid-arthritis drug outperformed AbbVie’s (ABBV) market-leading Humira in a clinical trial, sending both stocks higher. The study’s primary endpoint for the drug baricitinib was simply to do better than the placebo as measured on the ACR20 test, which signifies at least a 20% improvement in symptoms. But the drug also outperformed Humira, both on the Scalper1 News
Scalper1 News